Shanghai Shen Lian Biomedical Corporation (688098.SH): A total of 0.832% of shares have been repurchased.

On March 4th, Gelonghui reported that Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that as of February 28, 2025, the company had repurchased a total of 3,416,473 shares through a dedicated repurchase account via centralized bidding, accounting for 0.8320% of the total share capital of the company. The highest price for the repurchase was 6.29 yuan per share, the lowest price was 5.47 yuan per share, and the total amount paid was 19,995,169.13 yuan (excluding transaction fees such as stamp duty and trading commissions).

Gelonghui FinanceMar 4 16:56

Shen Lian Biomedical Obtains Certification, Production License for New Vaccine Lines

MT NewswiresFeb 28 16:03

Shenlian Biotech: 2024 Annual Results Express Announcement

SZSIFeb 28 00:00 · Announcements

2024 Annual Results Express Announcement

SZSIFeb 28 00:00 · Announcements

Shanghai Shen Lian Biomedical Corporation (688098.SH): Obtained the "Veterinary Drug GMP Certificate" and "Veterinary Drug Manufacturing License."

On February 27, Gelonghui reported that Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that its Lanzhou branch has recently passed the veterinary drug GMP acceptance and obtained the "Veterinary Drug GMP Certificate" and "Veterinary Drug Production License" issued by the Gansu Provincial Animal Husbandry and Veterinary Bureau. New production lines for cell suspension culture virus inactivated vaccines (including cell suspension culture virus subunit vaccines), cell suspension culture subunit vaccines, and bacterial inactivated vaccines have all passed the veterinary drug GMP acceptance.

Gelonghui FinanceFeb 27 17:03

Express News | Shanghai Shen Lian Biomedical Corporation: The subsidiary Ben Tian Cheng plans to increase its capital by 60 million yuan in Shi Zhi Yuan, holding 20.48% stake.

BreakingsFeb 5 17:48